Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

USPSTF Lowers the Recommended Age for CRC Screenings, Mandating Insurance Coverage

May 18, 2021
By Audrey Sternberg
News
Article

Recommendations published in JAMA are set to change colorectal cancer screening guidance for all individuals in the United States.

An update to the U.S. Preventive Services Task Force (USPSTF) recommendations now indicate that screening for colorectal cancer (CRC) should begin at age 45 years for all patients regardless of baseline characteristics, according to guidelines published in JAMA.1

This is a follow-up to draft guidance that was issued in October 2020 amending the recommended age of screening from 50 to 45 years of age and will mandate insurance coverage of screening for CRC.

These efforts by the task force are in large part a reaction to the alarming rise in the incidence of young-onset CRC, which occurs in patients younger than 50 years of age. By 2040, this is projected to be the leading cause of cancer deaths in patients ages 20 to 49 years.

This increasing incidence has been documented since the 1990s, but the proportion of patients with young-onset disease has accelerated rapidly over the last 10 years, with 11% of colon cancers and 15% of rectal cancers occurring in patients under the age of 50 years in 2020 compared with just 5% and 9%, respectively, in 2010.

“Clearly the USPSTF recommendation to start screening at age 45 will not be enough to catch those young people who are being diagnosed, but we must take bold steps to translate the lowered age of beginning screening into meaningful decreases in CRC incidence and mortality,” Kimmie Ng, MD, MPH, director of the Young-Onset Colorectal Cancer Center at Dana-Farber Cancer Institute and author of an accompanying editorial, said in a press release.2,3 “Lowering the recommended age to initiate screening will make colorectal cancer screening available to millions more people in the United States, and hopefully many more lives will be saved by catching colorectal cancer earlier, as well as by preventing colorectal cancer.”

Age 45 was selected by the task force based on evidence that averting more early deaths was possible versus starting at age 50 with a relatively small increase in the number of complications from colonoscopy. Of note, the new recommendation does not change guidance regarding screening in older individuals, with patients aged 76 to 85 years recommended for selective screening only.

In the editorial, Ng and colleagues point out that screenings at age 45 will not be enough to catch all cases of early-onset CRC, as the rate of colon cancer shows the steepest increase in patients aged 20 to 29 years at 2% versus 1.3% in those 40 to 49 years. Corresponding rates in rectal cancer were 3.2% and 2.3%, respectively.

“We are now seeing patients even younger than 45—in their 20s and 30s—who are being diagnosed with this cancer and often at very late stages,” Ng said. “Clearly the USPSTF recommendation to start screening at age 45 will not be enough to catch those young people who are being diagnosed.”

With the prior recommendations, less than 70% of patients who were eligible for screening received the preventative benefit, with patients who are uninsured or underinsured, those with lower incomes, and racial and ethnic minorities being disproportionately underserved. CRC is a disease that disproportionately affects African Americans, as they have a 20% greater likelihood of developing the tumor and a 40% greater risk of dying from it. As such, Ng and colleagues said addressing these public health barriers will be necessary to raise screening adherence.

References

1. US Preventive Services Task Force. Screening for Colorectal CancerUS Preventive Services Task Force Recommendation Statement. JAMA. 2021;325(19):1965-1977. doi:10.1001/jama.2021.6238

2. Ng K, May FP, Schrag D. US Preventive Services Task Force Recommendations for Colorectal Cancer ScreeningForty-Five Is the New Fifty. JAMA. 2021;325(19):1943-1945. doi:10.1001/jama.2021.4133

'45 is the new 50' as age for colorectal cancer screening is lowered. News release. Dana-Farber Cancer Institute. May 18, 2021. Accessed May 18, 2021. https://bit.ly/3bBK1DT

Recent Videos
Experts weigh in on tumor-informed testing, false positives, relevant trial data, and other key concepts related to circulating tumor DNA.
Hydration and a healthy, well-balanced diet may mitigate fatigue among patients undergoing treatment for cancer.
Bland foods, such as crackers and chicken noodle soup, as well as fluids with electrolytes, may help stave off treatment-related nausea.
According to Denise B. Reynolds, RD, patients eating well should not be experiencing nutritional deficiencies during cancer treatment.
Related Content
Advertisement

Acknowledging Mortality and Death in Cancer Care

Acknowledging Mortality and Death in Cancer Care

Ariana Pelosci
September 29th 2025
Article

In the oncology setting, having discussions about mortality and death may be daunting for patients, but is vital and inevitable.


Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.

Diving Into the Practical Applications of ctDNA in Oncology Care

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Arnab Basu, MBBS, MPH, FACP
September 25th 2025
Podcast

Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.


Efficacy data from the phase 1/2a STELLA trial evaluating alnodesertib plus irinotecan in those with ATM-negative disease support the regulatory decision.

Alnodesertib Receives FDA Fast Track Designation For ATM– Metastatic CRC

Roman Fabbricatore
September 24th 2025
Article


How to Discuss Death: A Conversation of Mortality in Cancer Care

How to Discuss Death: A Conversation of Mortality in Cancer Care

Daniel C. McFarland, DO;William Breitbart, MD
September 22nd 2025
Podcast

Daniel C. McFarland, DO; and guest William S. Breitbart, MD, discuss the critical role of meaning-centered therapy in addressing the psychosocial needs of patients with cancer.


Greater regulatory and policy clarity may better optimize clinician use of artificial intelligence in treating patients with cancer.

Advancing AI in Oncology: Critical Considerations for Clinical Practice

Roman Fabbricatore
September 19th 2025
Article

Greater regulatory and policy clarity may better optimize clinician use of artificial intelligence in treating patients with cancer.


An independent data monitoring committee recommended the continuation of the phase 2 AMPLIFY-7P trial evaluating ELI-002 7P in PDAC in August 2025.

ELI-002 7P Elicits T Cell Responses in Mutant KRAS-Driven Tumors

Roman Fabbricatore
September 18th 2025
Article

An independent data monitoring committee recommended the continuation of the phase 2 AMPLIFY-7P trial evaluating ELI-002 7P in PDAC in August 2025.

Related Content
Advertisement

Acknowledging Mortality and Death in Cancer Care

Acknowledging Mortality and Death in Cancer Care

Ariana Pelosci
September 29th 2025
Article

In the oncology setting, having discussions about mortality and death may be daunting for patients, but is vital and inevitable.


Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.

Diving Into the Practical Applications of ctDNA in Oncology Care

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Arnab Basu, MBBS, MPH, FACP
September 25th 2025
Podcast

Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.


Efficacy data from the phase 1/2a STELLA trial evaluating alnodesertib plus irinotecan in those with ATM-negative disease support the regulatory decision.

Alnodesertib Receives FDA Fast Track Designation For ATM– Metastatic CRC

Roman Fabbricatore
September 24th 2025
Article


How to Discuss Death: A Conversation of Mortality in Cancer Care

How to Discuss Death: A Conversation of Mortality in Cancer Care

Daniel C. McFarland, DO;William Breitbart, MD
September 22nd 2025
Podcast

Daniel C. McFarland, DO; and guest William S. Breitbart, MD, discuss the critical role of meaning-centered therapy in addressing the psychosocial needs of patients with cancer.


Greater regulatory and policy clarity may better optimize clinician use of artificial intelligence in treating patients with cancer.

Advancing AI in Oncology: Critical Considerations for Clinical Practice

Roman Fabbricatore
September 19th 2025
Article

Greater regulatory and policy clarity may better optimize clinician use of artificial intelligence in treating patients with cancer.


An independent data monitoring committee recommended the continuation of the phase 2 AMPLIFY-7P trial evaluating ELI-002 7P in PDAC in August 2025.

ELI-002 7P Elicits T Cell Responses in Mutant KRAS-Driven Tumors

Roman Fabbricatore
September 18th 2025
Article

An independent data monitoring committee recommended the continuation of the phase 2 AMPLIFY-7P trial evaluating ELI-002 7P in PDAC in August 2025.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.